1. Chairs Sven Mahner (Germany) Antonio González-Martín (Spain)
CHANGING THE NATURAL DISEASE COURSE IN OVARIAN CANCER – the role of PARPi maintenance
Chairs
Sven Mahner (Germany)
Antonio González-Martín (Spain)
ESMO 2018
Munich, Germany

2. WELCOME & INTRODUCTION
Prof Dr Sven Mahner, MD
Chair and Director
Department of Obstetrics & Gynaecology University Hospital Munich,
Ludwig-Maximilians-University, Munich, Germany

3. Faculty and disclosures
Prof Dr Sven Mahner Munich, Germany
Dr Rebecca Kristeleit London, UK
Financial support, honoraria and grants from: AstraZeneca, Bayer, Clovis, GSK, Medac, MSD, Pharmamar, Roche, Sensor Kinesis, Tesaro, Teva
AstraZeneca, Clovis, InCyte, Roche, TESARO
Dr Antonio González-Martín Madrid, Spain
Dr Axel Walther Bristol, UK
AstraZeneca, Clovis Oncology, Roche, TESARO
Educational grant from AstraZeneca, consulting fee and educational grants from TESARO
Dr Maurizio D’Incalci Milan, Italy
Scientific boards and consultancy for TESARO and Pharma Mar

4. Housekeeping ASK-THE-FACULTY.COM/ESMO2018 Please silence mobile phones
We look forward to your questions…
… ask the faculty online!

5. Agenda Time Presentation Presenter 13:00 – 13:15
Welcome and Introduction
Evolution of PARPi in ovarian cancer
Sven Mahner
13:15 – 13:35
Examining the relevant facts and new insights on PARP inhibition
Maurizio D’Incalci
13:35 – 13:45
Maintenance therapy with PARPi
13:45 – 14:05
Presenting the latest clinical evidence on PARPi in maintenance therapy
Rebecca Kristeleit
14:05 – 14:25
Practical experience with PARPi in ovarian cancer maintenance
Axel Walther
14:25 – 14:35
Conclusion
Antonio González-Martín

6. Symposium objectives
Review the concept of maintenance therapy in ovarian cancer
Differentiate the available PARP inhibitors
Examine clinical study evidence on PARP inhibitors
Discuss PARP inhibitor maintenance therapy in clinical practice